课题基金 / 基金详情

Developing eTACs as a novel method of tolerance in Type 1 Diabetes

Developing eTACs as a novel method of tolerance in Type 1 Diabetes
开发 eTAC 作为 1 型糖尿病耐受的新方法
批准号:
8672284
负责人:
Mark S Anderson
金额:
$34.31万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-04-02 至 2019-03-31

项目摘要

项目成果

Mark S Anderson的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):免疫系统受到多层调节,促进对自身的耐受性,对预防自身免疫性疾病(如1型糖尿病)至关重要。自身免疫调节因子(Aire)基因是维持免疫耐受的关键因素。Aire被鉴定为人类自身免疫性综合征自身免疫性多腺综合征1型的缺陷基因,突出了该基因在耐受性中的关键重要性。Aire在特化的胸腺髓上皮细胞(mTECs)中起作用,促进数百种自身抗原的表达,目的是清除正在发育的自身反应性T细胞,这一过程被称为负选择。最近,我们在外周淋巴器官中发现的一种独特的抗原呈递细胞群中描述了一个额外的Aire作用位点,我们称之为胸腺外空气表达细胞(eTACs)。与mtec一样,Aire在eTACs中促进许多自身抗原的表达,这些抗原与胸腺中Aire控制的抗原不同,这表明eTACs在促进外周细胞耐受方面具有互补作用。事实上,eTACs能够将自身抗原呈递给外周T细胞,导致自身反应细胞的缺失或功能失活,从而防止自身免疫。关于这种新型细胞类型还有很多未知之处;然而,eTACs的骨髓起源的发现打开了扩展和操纵这种细胞类型的潜力,用于促进自我耐受性的治疗应用。我们已经开发了一套强大的遗传工具,通过与其他类型的抗原呈递细胞的比较,使我们能够定义这些细胞的生长和发育,并确定潜在的外周耐受性诱导的独特途径。我们假设eTACs代表了一种独特的apc耐受性群体,在介导外周耐受性中起重要作用,可以作为耐受性诱导的新治疗靶点。因此,我们的具体目标是:(1)定义和表征eTAC的谱系和生长需求,(2)定义eTAC作用的位点和机制,以及(3)确定eTACs功能的丧失和获得如何调节T1D模型中的疾病。综上所述,我们的研究将有助于确定eTACs的起源,它们增强耐受性的机制,以及我们如何利用它们预防1型糖尿病和其他自身免疫性疾病。
英文摘要
DESCRIPTION (provided by applicant): The immune system is subject to multiple layers of regulation that promote tolerance to self and that are critical for the prevention of autoimmune diseases, such as Type 1 diabetes. A key player in the maintenance of immune tolerance is the Autoimmune Regulator (Aire) gene. Aire was identified as the defective gene in the human autoimmune syndrome Autoimmune Polyglandular Syndrome Type 1, highlighting the critical importance of this gene in tolerance. Aire acts within specialized medullary thymic epithelial cells (mTECs) to promote the expression of hundreds of self-antigens for the purpose of removing developing self-reactive T cells, a process known as negative selection. Recently, we have described an additional site of Aire action within a unique population of antigen-presenting cells found in peripheral lymphoid organs that we have termed extra-thymic Aire-expressing cells (eTACs). As in mTECs, Aire acts in eTACs to promote the expression of many self-antigens that are distinct from those controlled by Aire in the thymus, suggesting a complementary role of eTACs in promoting tolerance in the periphery. Indeed, eTACs are capable of presenting self-antigens to peripheral T cells to cause deletion or functional inactivation of the self-reactive cells, thus preventing autoimmunity. Much remains unknown about this novel cell type; however, the discovery of the bone-marrow origins of eTACs opens up the potential for expansion and manipulation of this cell type for therapeutic applications in promoting self-tolerance. We have developed a powerful set of genetic tools that will allow us to define the growth and development of these cells as well as identify potentially unique pathways of peripheral tolerance induction, through comparisons with other types of antigen-presenting cells. We hypothesize that eTACs represent a unique tolerogenic population of APCs with an important role in mediating peripheral tolerance and can serve as a novel therapeutic target for tolerance induction. Therefore, our specific aims are: (1) to define and characterize the lineage and growth requirements of eTACs, (2) to define the sites and mechanisms of eTAC action, and (3) to determine how loss and gain of function in eTACs can modulate disease in models of T1D. Taken together, our studies will help determine origins of eTACs, the mechanisms by which they enforce tolerance, and how we may employ them in the prevention of Type 1 diabetes and other autoimmune diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Administrative Core
Project 2: STAT3 as a trigger for T1D
STAT3 variants as a rheostat of immune tolerance
Tuning peptide specifities for T cell tolerance in Type 1 diabetes
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: